ACAD ACADIA Pharmaceuticals Inc.

-0.01  -0%
Previous Close 25.79
Open 25.89
Price To Book 8.89
Market Cap 3,709,287,782
Shares 143,882,381
Volume 1,047,626
Short Ratio
Av. Daily Volume 1,079,711

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced April 25, 2019.
Pimavanserin - CLARITY-2
Adjunctive Treatment in Patients With Major Depressive Disorder
Phase 2 data due year-end 2019.
Pimavanserin - Advance
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 data due mid-2019.
Pimavanserin - Enhance
Adjunctive treatment of schizophrenia
Announced October 4, 2017 that trial will be discontinued.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016. Additional dose approval announced June 29, 2018.
Parkinson’s disease psychosis (PDP)
Phase 3 interim data 2H 2019 with final data due 2020.
Pimavanserin - Harmony
Alzheimer’s disease psychosis
Phase 3 trial to be initiated 4Q 2019.
Rett Syndrome

Latest News

  1. New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
  2. See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
  3. Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?
  4. When Will ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Turn A Profit?
  5. ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
  6. ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
  7. Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT
  8. Why Acadia Pharmaceuticals Stock Slumped in April
  9. ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
  10. Acadia Pharmaceuticals (ACAD) Q1 2019 Earnings Call Transcript
  11. Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Tops Revenue Estimates
  12. Acadia: 1Q Earnings Snapshot
  13. ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
  14. Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. (ACAD)?
  15. Analysts point to potential Biogen M&A options after Alzheimer's failure
  16. ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
  17. Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
  18. Should ACADIA Pharmaceuticals (NASDAQ:ACAD) Be Disappointed With Their -30% Profit?